Network metaanalysis and cost per responder of tumor necrosis factor, interleukin, and phosphodiesterase inhibitors in the treatment of psoriatic arthritis

被引：0
|
作者：
Strand, Vibeke [1 ]
Husni, M. Elaine [2 ]
Griffith, Jenny [3 ]
Betts, Keith [4 ]
Beppu, Marci [3 ]
Song, Yan [4 ]
Ganguli, Arijit [3 ]
机构：
[1] Stanford Univ, Palo Alto, CA 94304 USA
[2] Cleveland Clin, Cleveland, OH 44106 USA
[3] AbbVie Inc, N Chicago, IL USA
[4] Anal Grp Inc, Boston, MA USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2016年 / 74卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
2534
引用
收藏
页码：AB260 / AB260
页数：1
相关论文
共 50 条
  • [1] Network Meta-Analysis and Cost Per Responder of Tumor Necrosis Factor-α and Interleukin Inhibitors in the Treatment of Active Ankylosing Spondylitis
    Betts K.A.
    Griffith J.
    Song Y.
    Mittal M.
    Joshi A.
    Wu E.Q.
    Ganguli A.
    Rheumatology and Therapy, 2016, 3 (2) : 323 - 336
  • [2] Tumor necrosis factor inhibitors in psoriatic arthritis
    Mantravadi, Santhi
    Ogdie, Alexis
    Kraft, Walter K.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (08) : 899 - 910
  • [3] Network meta-analysis and cost per responder of targeted Immunomodulators in the treatment of active psoriatic arthritis
    Strand V.
    Elaine Husni M.
    Betts K.A.
    Song Y.
    Singh R.
    Griffith J.
    Beppu M.
    Zhao J.
    Ganguli A.
    BMC Rheumatology, 2 (1)
  • [4] Network Meta-Analysis of Tumor Necrosis Factor, Interleukins, and Phosphodiesterase-4 Inhibitor in the Treatment of Psoriatic Arthritis
    Strand, Vibeke
    Husni, M. Elaine
    Reichmann, William
    Betts, Keith
    Griffith, Jenny
    Song, Yan
    Beppu, Marci
    Ganguli, Arijit
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [5] Potential of tumor necrosis factor inhibitors in psoriasis and psoriatic arthritis
    Krueger, G
    Callis, K
    ARCHIVES OF DERMATOLOGY, 2004, 140 (02) : 218 - 225
  • [6] Discontinuation of Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis and Psoriasis
    Wolfe, Sophia
    Cheng, Elizabeth
    Ganuthula, Kavya
    Fang, Meika
    Kerr, Gail
    Walsh, Jessica
    Chang, Elizabeth
    Raychaudhuri, Siba
    Brees, Kyle
    Dellavalle, Robert
    Reimold, Andreas
    Caplan, Liron
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 3825 - 3827
  • [7] TUMOR NECROSIS FACTOR INHIBITORS PERSISTENCE IN PSORIATIC ARTHRITIS PATIENTS
    Vieira-Sousa, E.
    Eusebio, M.
    Avila-Ribeiro, P.
    Khmelinskii, N.
    Machado, A. R.
    Martins-Rocha, T.
    Bernardes, M.
    Santos-Faria, D.
    Leite Silva, J.
    Santos, H.
    Miguel, C.
    Carvalho, P.
    Costa, T.
    Teixeira, L.
    Meirinhos, T.
    Nero, P.
    Santos, M. J.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2018, 36 (04) : 731 - 732
  • [8] Soluble Biomarkers Associated with Response to Treatment with Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis
    Chandran, Vinod
    Shen, Hua
    Pollock, Remy A.
    Pellett, Fawnda J.
    Carty, Adele
    Cook, Richard J.
    Gladman, Dafna D.
    JOURNAL OF RHEUMATOLOGY, 2013, 40 (06) : 866 - 871
  • [9] A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA
    Elizabeth Wehler
    Natalie Boytsov
    Claudia Nicolay
    Oscar Herrera-Restrepo
    Stacey Kowal
    PharmacoEconomics, 2020, 38 : 39 - 56
  • [10] A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA
    Wehler, Elizabeth
    Boytsov, Natalie
    Nicolay, Claudia
    Herrera-Restrepo, Oscar
    Kowal, Stacey
    PHARMACOECONOMICS, 2020, 38 (01) : 39 - 56
12345